TY - JOUR
T1 - Southwestern internal medicine conference
T2 - Drug therapy in the management of acute renal failure
AU - Cronin, R. E.
PY - 1986/1/1
Y1 - 1986/1/1
N2 - Pharmacologic intervention aimed at altering the natural history of acute renal failure is a routine practice without scientific support of efficacy. Oliguria has become a separate disease entity with an apparent disregard for the underlying condition that caused it. Volume expression is clearly beneficial in preventing many volume depleted patients from progressing to acute renal failure. While mannitol and furosemide have been used to 'convert' oliguric acute renal failure to the more easy to manage non-oliguric acute renal failure, published reports suggest that responders were not as ill as non-responders. The use of dopamine to increase urine flow in patients with established acute renal failure is the current fashion, but there is little evidence that this drug raises the glomerular filtration rate or shortens the course of acute renal failure. These pharmacologic therapies increase the complexity and cost of care with little tangible evidence of benefit to the patient or the physician caring for the patient.
AB - Pharmacologic intervention aimed at altering the natural history of acute renal failure is a routine practice without scientific support of efficacy. Oliguria has become a separate disease entity with an apparent disregard for the underlying condition that caused it. Volume expression is clearly beneficial in preventing many volume depleted patients from progressing to acute renal failure. While mannitol and furosemide have been used to 'convert' oliguric acute renal failure to the more easy to manage non-oliguric acute renal failure, published reports suggest that responders were not as ill as non-responders. The use of dopamine to increase urine flow in patients with established acute renal failure is the current fashion, but there is little evidence that this drug raises the glomerular filtration rate or shortens the course of acute renal failure. These pharmacologic therapies increase the complexity and cost of care with little tangible evidence of benefit to the patient or the physician caring for the patient.
UR - http://www.scopus.com/inward/record.url?scp=0022760645&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0022760645&partnerID=8YFLogxK
U2 - 10.1097/00000441-198608000-00010
DO - 10.1097/00000441-198608000-00010
M3 - Article
C2 - 3089011
AN - SCOPUS:0022760645
SN - 0002-9629
VL - 292
SP - 112
EP - 119
JO - The American journal of the medical sciences
JF - The American journal of the medical sciences
IS - 2
ER -